Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 2Recurrence 1Meningeal Neoplasms 1Inhibition, Psychological 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 10Specimen Handling 6Radiotherapy 6Magnetic Resonance Spectroscopy 6pembrolizumab 3Bevacizumab 3trametinib 2Surgical Procedures, Operative 2Radiation 2Magnetic Resonance Imaging 2Leukapheresis 2Genetic Therapy 2Fluorodeoxyglucose F18 2Biopsy 2vorasidenib 1trastuzumab deruxtecan 1ribociclib 1regorafenib 1olutasidenib 1mirdametinib 1lorlatinib 1dabrafenib 1apixaban 1aflibercept 1abexinostat 1Vinblastine 1Tretinoin 1Therapies, Investigational 1Restraint, Physical 1Re-Irradiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Astrocytoma × AZD1390 × Clear all
NCT06894979 2026-05-15

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Children's Oncology Group

Phase 1 Recruiting
54 enrolled
CNS

Astrocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡